3 Reasons to Avoid RGEN and 1 Stock to Buy Instead [Yahoo! Finance]
Repligen Corporation (RGEN)
Last repligen corporation earnings: 2/20 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
repligen.com/investors
Company Research
Source: Yahoo! Finance
Is now the time to buy Repligen, or should you be careful about including it in your portfolio? See what our analysts have to say in our full research report, it's free Why Do We Think Repligen Will Underperform? We're cautious about Repligen. Here are three reasons why RGEN doesn't excite us and a stock we'd rather own. 1. Fewer Distribution Channels Limit its Ceiling Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right. With just $738.3 million in revenue over the past 12 months, Repligen is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, a
Show less
Read more
Impact Snapshot
Event Time:
RGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGEN alerts
High impacting Repligen Corporation news events
Weekly update
A roundup of the hottest topics
RGEN
News
- Repligen (RGEN) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Repligen (RGEN) had its price target lowered by UBS Group AG from $200.00 to $195.00. They now have a "buy" rating on the stock.MarketBeat
- Repligen (RGEN) had its price target lowered by Barclays PLC from $200.00 to $175.00. They now have an "overweight" rating on the stock.MarketBeat
- Repligen (RGEN) had its price target lowered by Wells Fargo & Company from $190.00 to $180.00. They now have an "overweight" rating on the stock.MarketBeat
- Repligen (RGEN) had its "overweight" rating reaffirmed by KeyCorp.MarketBeat
RGEN
Earnings
- 2/24/26 - Beat
RGEN
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- RGEN's page on the SEC website